Introduction
Haemophilia is an inherited X-chromosome-linked deficiency in clotting factors that results in a bleeding disorder. Individuals with severe haemophilia can spontaneously bleed into joints, muscles, body cavities, and soft tissue. These complications may not only lead to severe and sustained disability but also to extreme pain, impairing the patient's overall quality of life [1, 2] .
There are two therapeutic strategies: on-demand and prophylactic treatment. On-demand treatment is defined as factor concentrate replacement during an acute bleeding episode or when undergoing surgery. This strategy seems to be the standard practice in most countries [3] . Alternatively, patients can be treated by prophylactic clotting factor substitution [4, 5] . Usually, quantities of factor are given two or three times per week. European guidelines recommend prophylactic treatment for children with severe haemophilia [6, 7] . Prophylactic treatment should start from early childhood onward after the first joint bleed and the dosages should be individually adjusted according to the bleeding frequency. Primary prophylaxis has been defined as starting before the onset of serial bleeding and when all joints are still unaffected [4] .
Clinical studies have shown significant improvements in clinical and economic outcomes with the use of prophylactic treatment. Results include avoidance of joint and other bleeding, reduced disability, lower rates of hospitalizations, and lower productivity losses through time off from school or work [8] [9] [10] [11] [12] . Improvements in outcomes, Original article 477 however, were achieved at considerable cost. To our knowledge, only two such studies have extrapolated mean lifetime costs of on-demand and prophylactic treatment [13, 14] . One, a long-term US model, measured only avoided bleeds as an outcome and did not measure quality-adjusted life years (QALYs) gained [13] . The other, a Markov model by Miners et al. [14] appears to be a more sophisticated attempt at weighing the longterm costs and benefits of primary prophylaxis. It is, however, based on multiple assumptions that should be critically evaluated.
Furthermore, the clinical outcomes assessment of healthrelated quality of life (HRQoL) is important in determining the impact of a treatment strategy. HRQoL is measured by generic or disease-specific quality-of-life instruments or by preference-based utility instruments. Patient preferences are typically measured as a 'utility'. Utilities express the relative value of health for a specific health state as a single number on a scale ranging from 0 (for death) to 1 (for perfect health). Utilities are most often used in economic evaluations because they allow the derivation of a QALY statistic. One QALY is equivalent to 1 year of perfect health [15] . The most widely used generic measure in clinical trials is the Short Form-36 (SF-36) health survey [1, 2, 9, 10, 16, 17] . The main shortcoming of the SF-36 in economic evaluations is that its eight separate dimensions cannot be formally combined into a single utility value [18] . Brazier and colleagues presented an algorithm to estimate a single preference-based index (Short Form-6D (SF-6D) health state classification) from the SF-36 profile. This algorithm provides the opportunity for undertaking costeffectiveness analysis using existing SF-36 data sets and for evaluating costs per QALYs gained in costeffectiveness analyses [19] .
The objective of the study was to assess the cost effectiveness of prophylactic treatment compared with ondemand treatment in patients with severe haemophilia A and B over a 1-year period from the third-party payers' perspective.
Methods
Baseline data and study population Baseline data were collected by the European Haemophilia Economic Study Group to compare various health outcomes associated with on-demand and prophylactic treatment in European haemophilia patients [12] . This multicentre study of haemophilia care in Europe was initiated as a cross-sectional survey of all haemophilia patients treated with factor concentrates at 18 participating haemophilia treatment centres (HTCs) in 10 European countries. Physicians at the respective HTCs classified patients into on-demand or prophylactic groups in relation to the treatment modality. Reasons for prophylaxis were a higher bleeding frequency and higher physical and mental burden. Prophylactic patients were treated with coagulating factor at least two to three times per week and for a minimum of 6 months. The observation period of this baseline study was 6 months. Findings for clinical endpoints and quality of life based on the multidimensional SF-36 have been reported elsewhere [12, 16] .
For the cost-effectiveness analysis we chose four countries (Germany, Sweden, United Kingdom, The Netherlands) due to similar health care systems and comparable haemophilia treatment patterns. Patients eligible for recruitment included those with severe haemophilia A and B (factor level <1%) who had not developed an inhibitor against the coagulating factor, who had a minimum age of 14 years and who were receiving medical care at the HTC between January 1996 and January 1998 (the enrolment phase of the study).
Measures
Three questionnaires were used for data collection. The first was completed by the physician at the respective HTC and required data from the patient's record and a physical examination. The following data were collected retrospectively over 6 months: demographic data (e.g. age, disability), disease information (e.g. haemophilia type, severity degree, co-morbidities, annual consumption of clotting factor), information on health-related resource utilization (e.g. number of outpatient visits at family doctor, outpatient visits at HTC, length of hospitalization, days off work or school, medication and surgical interventions). Haemophilic arthropathy was measured by the physician using the physical examination score (PES) [20] . The second questionnaire was completed by the patient and comprised the SF-36 health survey [21] . The third questionnaire was completed by physicians at four HTCs (in Germany, the United Kingdom, The Netherlands and Sweden) to get information on factor prices, hospital fees, and charges for outpatient care in order to calculate direct medical costs.
Statistical analysis
To predict utilities and to adjust the predicted utilities for further covariates, multiple regression analysis was performed. Utilities were the dependent variables using age, disability, bleeding frequency, physical examination score, hepatitis B virus (HBV) and HIV infection, and average amount of clotting factor as independent variables. For variables selection, the stepwise variable selection method was used, which was based on maximized adjusted R 2 statistics within variables with a P-value under 0.15. In addition, statistical interactions were evaluated.
The significance of differences in observed and expected utilities between on-demand and prophylactic therapy was examined by a two-sided unpaired Students' t-test. A P-value under 0.05 was considered as statistically significant.
Decision model and cost-effectiveness analysis
We examined the incremental cost-effectiveness ratio (ICER) of on-demand treatment compared with prophylactic treatment in patients with severe haemophilia A and B without inhibitors. The time horizon of the decision-analytic model was 1 year. Health effects were presented in terms of QALYs gained as well as in terms of the clinical outcome of avoided bleeds. We adopted the third-party payers' perspective and examined direct medical costs only. We did so because other studies indicated that these were the main cost drivers in haemophilia treatment, especially due to the high cost of clotting factor [13] .
Probabilities for clinical data (bleeds, PES, occurrence of HIV infection), utilization of health care resources and utilities were estimated from original patient data (n ¼ 506) [12] . We stratified all analyses by age group ( 30 years and >30 years) and HIV status because prophylaxis is recommended in younger patients with severe haemophilia and HIV infection has a substantial influence on HRQoL [16] .
Clinical effectiveness
Avoided joint bleeds and QALYs gained were chosen as clinical effectiveness endpoints. Clinical data were pooled across the four European countries to compute overall model parameters for bleeds and utilities. Patient utilities were derived from algorithms using the SF-6D. The development of the SF-6D algorithm was performed by Brazier et al. [19] . QALYs were calculated by multiplying predicted utilities by 1 year.
Resources and costs
We assessed direct medical costs from the third-party payers' perspective including medication cost (coagulation factor), hospitalization (normal and internal ward), outpatient treatment at the HTC, and outpatient treatment by the general practitioner. Data on resource utilization are based on the before-mentioned study with an observation period of 6 months. Data on resource utilization are based on the baseline study mentioned above, with an observation period of 6 months. Resource utilization was extrapolated for 1 year. Prices of resources were obtained for each country separately. For example, purchase prices for recombinant factor VIII were s0.95/ Unit in Germany, s0.71/Unit in Sweden, s0.86/Unit in The Netherlands and s0.75/Unit in the United Kingdom. An inpatient day (normal ward) was valued at s307 in Germany, s357 in Sweden, and s391 in the United Kingdom. For calculation of personal annual factor consumption, the annual amount of factor concentrate in international units per kilogram was multiplied by the patient's body weight. Costs of care were estimated by age group, treatment strategy, and country. For comparability, all costs were converted into euros using the following conversion on 29 August 2002: £1 sterling equalled s1.56916; US$1 equalled s1.02135. The index year was 2002.
Incremental cost-effectiveness analysis
The incremental cost-effectiveness ratio was defined as the difference in costs of on-demand treatment versus prophylaxis (in euros) divided by the difference in effectiveness (avoided bleeds and QALYs gained).
Sensitivity analyses
The robustness of the results of this cost-effectiveness analysis was explored using one-way sensitivity analyses. To reflect uncertainty of cost and utility data, all costs and utilities were varied by AE10%.
Results

Study population
Five hundred and six patients were included. Patients' characteristics are shown in Table 1 . The mean age was 35 AE 13 years (range 14-83). The majority of patients younger than 30 years were treated prophylactically (65%). Stratification by treatment strategy and age group showed that in patients 30 years or older, HBV and hepatitis C virus (HCV) infection occurred twice as often in the prophylactic group (HBV, n ¼ 59; HCV, n ¼ 111) as in the on-demand group (HBV, n ¼ 26; HCV, n ¼ 56). In patients older than 30 years, HBV and HCV infection was equally distributed in the two treatment strategies.
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Short Form-6D health state classification
The mean utility of the total cohort was 0.70 (95% confidence interval, 0.69-0.81). Patients 30 years or younger treated prophylactically reported significantly better utilities (0.76) than patients treated on-demand (0.73). In patients over 30 years, the utility improvement of patients with prophylaxis (0.68) versus those treated on demand (0.66) was smaller and not statistically significant (P ¼ 0.15). Patients infected with HIV had significantly lower utilities than those without HIV (0.68 versus 0.71; P ¼ 0.02). The association between observed utilities, annual number of joint bleeds, and PES is displayed in Figure 1 . With increasing number of joint bleeds per year, the utilities decreased and PES increased.
Multiple regression analysis for Short Form-6D
In patients 30 years or younger, occurrence of disability (regression coefficient, À0.031; P ¼ 0.073), increasing age (regression coefficient, À0.007; P ¼ 0.004) and increasing number of bleeds (regression coefficient, À0.002; P ¼ 0.003) indicated a reduction in utilities. In patients over 30 years, occurrence of disability (regression coeffi-cient À0.051; P ¼ 0.011), increasing age (regression coefficient À0.002; P ¼ 0.064) and presence of HBV infection indicated a reduction in utilities. Presence of HBV infection indicated an increase in utilities (regression coefficient 0.028; P ¼ 0.113).
Because of the presence of interaction terms, however, the regression coefficients for age, PES, average amount of clotting factor required, and occurrence of HIV and HBV could not be directly interpreted. Alternative models without interaction terms indicated a decrease in utilities associated with increasing age (regression coefficient À0.00267; P < 0.0001), increasing amount of clotting factor (regression coefficient À0.00066; P ¼ 0.0002), increasing PES (regression coefficient À0.00664; P ¼ 0.0023) and increasing bleeding frequency (regression coefficient À0.00173; P ¼ 0.0001). Prophylactic treatment increased utilities (regression coefficient 0.02941; P ¼ 0.0350). In these alternative models, presence of HIV and HBV infection was not significant (HIV regression coefficient À0.00327, P ¼ 0.7806; HBV regression coefficient 0.01310, P ¼ 0.2800). (We offer the reader the option to obtain additional results from the authors on request.) For our decision model, we used regression equations based on patient characteristics and treatment strategies to derive predicted utilities. The comparison of observed and predicted utilities is displayed in Table 2 . Observed and predicted utilities were similar, indicating a good internal validity of the prediction equations. Prophylactic therapy had a statistically significant beneficial effect on utilities in HIV-negative patients. Table 3 shows the medical resource utilization per patient per year which was extrapolated from data from the baseline study.
Cost-effectiveness-analysis
The mean annual direct medical costs per patient in the on-demand group ranged from s24 771 (>30 years) in the United Kingdom to s92 918 (>30 years) in Germany. For prophylaxis the mean annual direct medical costs per patient ranged from s112 727 (>30 years) in The Netherlands to s182 075 (>30 years) in Germany. Utility values of patients 30 years and >30 years versus number of bleeds and physical examination score (PES). Evaluated joints were knee, ankle, and hip. The maximum score was 15 points for the most severely affected joints. Patients treated prophylactically had fewer bleeds than patients treated on-demand. With prophylactic treatment, the incremental cost per avoided bleeding ranged from s6650 for patients 30 years and younger in Germany to s14 138 for patients over 30 years in Sweden (see Table 4 ).
The ICER for prophylactic versus on-demand treatment in 1 year for HIV-infected patients 30 years or less ranged from s1.24 million per QALY in Germany to s1.73 million per QALY in the United Kingdom ( 
Sensitivity analysis
Results were insensitive to changes in direct medical costs but partially sensitive to changes in quality of life. In all subgroups defined by HIV status and age, however, ICERs were greater than s500 000 per QALY, even after assuming a 10% utility increase in the prophylactic regimen. After decreasing utility by 10% in the prophylactic regimen, on-demand treatment was the dominant strategy for all evaluated subgroups.
Discussion
To our knowledge, the present study is the first to derive utilities from SF-36 health survey data in patients with severe haemophilia. Clinical outcomes and resource utilization of on-demand and prophylactic treatment strategies were compared. The utilities predicted by a multivariate function were combined with economic data to assess the incremental cost of prophylaxis per QALY gained as well as incremental cost per avoided bleeds.
In the present study, prophylaxis provides fewer joint bleeds per year and lower physical examination scores than on-demand therapy (Fig. 1) . Other studies have also demonstrated significant improvements in outcomes with the use of prophylactic treatment [3, 4, 8, [10] [11] [12] [22] [23] [24] .
Besides, our results showed that lower utilities were associated with increasing joint bleeding frequency and higher physical examination scores, which reflected more affected joints. Adjustment for age showed that
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Previous studies have also demonstrated positive effects of prophylaxis on quality of life and patient preferences [16, 25] . In a European outcome study, patients treated prophylactically reported significantly less bodily pain as ICER, incremental cost-effectiveness ratio. The strategy which is less effective at higher cost is called the dominated strategy.
well as better general health and physical functioning [16] . In a quality-of-life study, Naraine et al. [25] also showed that prophylaxis improved quality of life among healthy adults, parents of haemophilic children, and adult haemophiliacs.
Utilities were sensitive to age and co-morbidity (e.g. HIV infection). Patients with HIV infection had significantly lower utilities than non-infected haemophiliac patients ( Table 2 ). This corresponds with other studies that have shown the effect of HIV on quality of life [26, 27] . It remains for further studies to determine why prophylaxis is apparently more beneficial in young ( 30 years) HIVinfected patients than it is among HIV-negative haemophiliacs. Other studies have shown an increasing tendency toward bleeding among HIV-infected patients who took protease inhibitor drugs [28, 29] . Thus, it is possible that HIV-infected patients had a relatively higher benefit from prophylaxis than HIV-free haemophiliacs. This result reversed with increasing age, and prophylaxis had even smaller effects than treatment ondemand. It is possible that progression of HIV infection may have influenced utilities. To answer this, further quality-of-life studies, especially with older HIV-infected haemophiliacs, must be conducted.
Other quality of life studies which reported utilities compare favourably with the present study: median utilities (0.66, n ¼ 66) of severe haemophilia patients were reported by using the EQ-5D questionnaire [1] . Trippoli et al. [2] reported mean utilities of 0.81, 0.70, and 0.49 for patient ages 15-30, 31-45, and over 45 years, respectively, by using the EQ-5D. As in our study, HIV status was associated with lower mean utilities (0.55 versus 0.71). The utilities of haemophiliac patients in the present study are also comparable with other chronic diseases such as multiple sclerosis (mean utility 0.55) [30] or rheumatoid arthritis (mean utility 0.72) [31] .
In the second part of our study, we combined the predicted utilities with economic data and performed a cost-effectiveness analysis. Direct medical costs were determined for each country separately because of unique prices for clotting factor, for example, depending on included or excluded value added tax. Secondly, each country has specific treatment guidelines that specify the prescribed dosage of clotting factor. Therefore, total costs ranged from s24 771 for on-demand treatment in the United Kingdom to s194 564 for prophylaxis per patient and year in Sweden (Table 4 ). Cost for the Swedish cohort are comparable with the results of a recent cost of illness study which showed mean annual cost for patients older than 18 years: for on-demand treated patients, cost amounted to s51 518 and for prophylactically treated patients s147 939 [32] . In our study, costs for the Dutch cohort were lower than in the other countries, with exception of the British patients (younger than 30 years). This corresponds with the results of a study by van den Berg et al. [33] , which showed that the prophylactic regimen of a Dutch cohort was less costly than a Swedish cohort due to less use of clotting factor.
Avoiding one additional joint bleed would cost an additional s6700-s14 100. These incremental costeffectiveness ratios were higher than those reported by Miners et al. [22] (s858/avoided bleed), Szucs and Schramm [34] s1295 per avoided bleed) and Smith et al. [13] (s1124-s1410 per avoided bleed).
We identified only one prior economic study comparing the cost effectiveness of on-demand versus primary prophylactic treatment using a decision-analytic Markov model to simulate long-term consequences [14] . In this study, lifetime healthcare costs of on-demand treatment were s426 550. The lifetime cost for prophylaxis, however, was larger and accounted for s1 514 970 in a scenario with factor infusion every 56 h. The ICER for individuals receiving factor VIII was s76 060 per QALY gained. If patients were treated with factor IX, ICER was s13 490 per QALY [14] . As a result, these ICERs were lower than in our study.
There are several possible explanations for the differences between prior studies and ours. In a cost utility study Miners et al. [14] compared the lifetime costs and utilities of treating severe haemophiliacs on-demand versus primary prophylaxis. In the absence of randomized controlled studies, Miners et al. [14] used QALYs. The results of our sensitivity analysis indicate that the cost effectiveness of prophylaxis is likely to improve through better quality of life among patients treated prophylactically. If the utilities in the prophylactic group were 10% higher, the ICER of prophylaxis would be decreased from s1 236 000 to s541 000 per QALY.
A severe limitation of our study was that it was a retrospective analysis and all causal conclusions with regard to the differential effect of treatment regimens must be interpreted with caution. Furthermore, it should be noted that although our utility prediction functions showed good results in the goodness-of-fit test for internal validity, an external and prospective validation must be done. To avoid overoptimistic model fit, we restricted the number of variables examined in our regression analyses and we assumed linear relationships between predictors and outcomes. We examined this assumption for each continuous variable by plotting the residuals against that variable; no curvilinear patterns were observed. This suggests a satisfactory robustness of our prediction functions. The economic evaluation was limited by the fact that the cost structure was determined by expert questioning of a limited number of physicians. Moreover, costs of treatment of viral infections secondary to clotting factor infusion were not included in the model. Finally, most published guidelines for pharmacoeconomic evaluations recommend the adoption of a societal perspective. In addition to direct medical costs, the societal perspective includes direct non-medical costs and potential indirect costs [35] . The inclusion of costs to society in economic models is usually difficult, especially when reliable information on those costs is not available. Our study estimated the costs due to direct medical resource consumption from the perspective of the insurer as the payer. This perspective has been proposed because earlier studies, such as the European Socioeconomic Study on Haemophilia, have shown that the societal costs due to productivity losses caused by days lost from work or premature retirement were not the costs drivers as compared with the healthy population [36] .
In conclusion, considering incremental costs of prevented joint bleeds, the use of prophylactic treatment was overall more effective than on-demand therapy, especially in young haemophiliacs. If costs per QALY were taken into account, the situation was different; the use of prophylactic treatment was more effective than on-demand therapy, but at extremely high cost. On the basis of our analysis, however, it cannot be excluded that initiating prophylactic treatment at an early age may improve quality of life by preventing arthropathy in a cost-effective way. In older HIV-positive patients, the situation was different: on-demand treatment yielded better utilities at lower costs than prophylaxis. In consideration of these differences, we recommend taking into account specific patient characteristics such as age and comorbidities when deciding whether prophylaxis is suited for treatment in haemophiliac patients.
In the future, it will be important to investigate the longterm effectiveness and cost of haemophilia treatment strategies in prospective studies as well as the development of long-term decision-analytic Markov models including data from these prospective studies.
